Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


HDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 complex.

Vallières C, Fisher N, Antoine T, Al-Helal M, Stocks P, Berry NG, Lawrenson AS, Ward SA, O'Neill PM, Biagini GA, Meunier B.

Antimicrob Agents Chemother. 2012 Jul;56(7):3739-47. doi: 10.1128/AAC.00486-12.


Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex.

Biagini GA, Fisher N, Berry N, Stocks PA, Meunier B, Williams DP, Bonar-Law R, Bray PG, Owen A, O'Neill PM, Ward SA.

Mol Pharmacol. 2008 May;73(5):1347-55. doi: 10.1124/mol.108.045120.


Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex.

Siregar JE, Kurisu G, Kobayashi T, Matsuzaki M, Sakamoto K, Mi-ichi F, Watanabe Y, Hirai M, Matsuoka H, Syafruddin D, Marzuki S, Kita K.

Parasitol Int. 2015 Jun;64(3):295-300. doi: 10.1016/j.parint.2014.09.011.


Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).

Pidathala C, Amewu R, Pacorel B, Nixon GL, Gibbons P, Hong WD, Leung SC, Berry NG, Sharma R, Stocks PA, Srivastava A, Shone AE, Charoensutthivarakul S, Taylor L, Berger O, Mbekeani A, Hill A, Fisher NE, Warman AJ, Biagini GA, Ward SA, O'Neill PM.

J Med Chem. 2012 Mar 8;55(5):1831-43. doi: 10.1021/jm201179h.


Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum.

Stickles AM, de Almeida MJ, Morrisey JM, Sheridan KA, Forquer IP, Nilsen A, Winter RW, Burrows JN, Fidock DA, Vaidya AB, Riscoe MK.

Antimicrob Agents Chemother. 2015 Apr;59(4):1977-82. doi: 10.1128/AAC.04149-14.


Reconstructing the Qo site of Plasmodium falciparum bc 1 complex in the yeast enzyme.

Vallières C, Fisher N, Meunier B.

PLoS One. 2013 Aug 12;8(8):e71726. doi: 10.1371/journal.pone.0071726.


Design, synthesis and structure-activity relationships of (1H-pyridin-4-ylidene)amines as potential antimalarials.

Rodrigues T, Guedes RC, dos Santos DJ, Carrasco M, Gut J, Rosenthal PJ, Moreira R, Lopes F.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3476-80. doi: 10.1016/j.bmcl.2009.05.017.


Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression.

Fisher N, Abd Majid R, Antoine T, Al-Helal M, Warman AJ, Johnson DJ, Lawrenson AS, Ranson H, O'Neill PM, Ward SA, Biagini GA.

J Biol Chem. 2012 Mar 23;287(13):9731-41. doi: 10.1074/jbc.M111.324319.


Antimalarial quinolones: synthesis, potency, and mechanistic studies.

Winter RW, Kelly JX, Smilkstein MJ, Dodean R, Hinrichs D, Riscoe MK.

Exp Parasitol. 2008 Apr;118(4):487-97.


Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria.

Biagini GA, Fisher N, Shone AE, Mubaraki MA, Srivastava A, Hill A, Antoine T, Warman AJ, Davies J, Pidathala C, Amewu RK, Leung SC, Sharma R, Gibbons P, Hong DW, Pacorel B, Lawrenson AS, Charoensutthivarakul S, Taylor L, Berger O, Mbekeani A, Stocks PA, Nixon GL, Chadwick J, Hemingway J, Delves MJ, Sinden RE, Zeeman AM, Kocken CH, Berry NG, O'Neill PM, Ward SA.

Proc Natl Acad Sci U S A. 2012 May 22;109(21):8298-303. doi: 10.1073/pnas.1205651109.


Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors.

Dong CK, Urgaonkar S, Cortese JF, Gamo FJ, Garcia-Bustos JF, Lafuente MJ, Patel V, Ross L, Coleman BI, Derbyshire ER, Clish CB, Serrano AE, Cromwell M, Barker RH Jr, Dvorin JD, Duraisingh MT, Wirth DF, Clardy J, Mazitschek R.

Chem Biol. 2011 Dec 23;18(12):1602-10. doi: 10.1016/j.chembiol.2011.09.016.


Inhibiting Plasmodium cytochrome bc1: a complex issue.

Barton V, Fisher N, Biagini GA, Ward SA, O'Neill PM.

Curr Opin Chem Biol. 2010 Aug;14(4):440-6. doi: 10.1016/j.cbpa.2010.05.005. Review.


Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1.

Bueno JM, Herreros E, Angulo-Barturen I, Ferrer S, Fiandor JM, Gamo FJ, Gargallo-Viola D, Derimanov G.

Future Med Chem. 2012 Dec;4(18):2311-23. doi: 10.4155/fmc.12.177. Review.


Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site.

Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q.

Antimicrob Agents Chemother. 2000 Aug;44(8):2100-8.


Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action.

Birth D, Kao WC, Hunte C.

Nat Commun. 2014 Jun 4;5:4029. doi: 10.1038/ncomms5029.


Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae.

Kessl JJ, Ha KH, Merritt AK, Lange BB, Hill P, Meunier B, Meshnick SR, Trumpower BL.

J Biol Chem. 2005 Apr 29;280(17):17142-8.


Protonmotive pathways and mechanisms in the cytochrome bc1 complex.

Hunte C, Palsdottir H, Trumpower BL.

FEBS Lett. 2003 Jun 12;545(1):39-46. Review.


Saccharomyces cerevisiae-based mutational analysis of the bc1 complex Qo site residue 279 to study the trade-off between atovaquone resistance and function.

Song Z, Clain J, Iorga BI, Yi Z, Fisher N, Meunier B.

Antimicrob Agents Chemother. 2015 Jul;59(7):4053-8. doi: 10.1128/AAC.00710-15.

Items per page

Supplemental Content

Support Center